Comprehensive identification of genes driven by ERV9-LTRs reveals TNFRSF10B as a re-activatable mediator of testicular cancer cell death

Cell Death and Differentiation

Volumn 23, Issue 1, 2016, Pages 64-75

  Beyer, U ^a,b   Kronung S K ^a   Leha, A ^a   Walter, L ^c   Dobbelstein, M ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c GERMAN PRIMATE CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; COMPLEMENTARY DNA; DEATH RECEPTOR 5; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; HISTONE DEACETYLASE; ISOPROTEIN; TNFRSF10B PROTEIN, HUMAN; TNFRSF21 PROTEIN, HUMAN; TP63 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL SURVIVAL; CODING; CONTROLLED STUDY; ENDOGENOUS RETROVIRUS; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE IDENTIFICATION; GENOME; GERM CELL; HUMAN; HUMAN CELL; LONG TERMINAL REPEAT; MALE; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; TESTIS CANCER; TNFRSF10B GENE; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROMOTER REGION; TESTIS TUMOR; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; ENDOGENOUS RETROVIRUSES; GENE EXPRESSION REGULATION, NEOPLASTIC; GERM CELLS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MALE; PROMOTER REGIONS, GENETIC; PROTEIN ISOFORMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, MESSENGER; TERMINAL REPEAT SEQUENCES; TESTICULAR NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84949530283     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2015.68     Document Type: Article

References (64)

1. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J., et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
2. Jern P, Coffin JM. Effects of retroviruses on host genome function. Annu Rev Genet 2008; 42: 709-732.
3. Beyer U, Moll-Rocek J, Moll UM, Dobbelstein M. Endogenous retrovirus drives hitherto unknown proapoptotic p63 isoforms in the male germ line of humans and great apes. Proc Natl Acad Sci USA 2011; 108: 3624-3629.
4. Liu M, Eiden MV. Role of human endogenous retroviral long terminal repeats (LTRs) in maintaining the integrity of the human germ line. Viruses 2011; 3: 901-905.
5. Di Cristofano A, Strazzullo M, Longo L, La Mantia G. Characterization and genomic mapping of the ZNF80 locus: expression of this zinc-finger gene is driven by a solitary LTR of ERV9 endogenous retroviral family. Nucleic Acids Res 1995; 23: 2823-2830.
6. Di Cristofano A, Strazzullo M, Parisi T, La Mantia G. Mobilization of an ERV9 human endogenous retroviral element during primate evolution. Virology 1995; 213: 271-275.
7. Chen HJ, Carr K, Jerome RE, Edenberg HJ. A retroviral repetitive element confers tissuespecificity to the human alcohol dehydrogenase 1C (ADH1C) gene. DNA Cell Biol 2002; 21: 793-801.
8. Heinz S, Krause SW, Gabrielli F, Wagner HM, Andreesen R, Rehli M. Genomic organization of the human gene HEP27: alternative promoter usage in HepG2 cells and monocytederived dendritic cells. Genomics 2002; 79: 608-615.
9. Bekpen C, Marques-Bonet T, Alkan C, Antonacci F, Leogrande MB, Ventura M., et al. Death and resurrection of the human IRGM gene. PLoS Genet 2009; 5: e1000403.
10. Plant KE, Routledge SJ, Proudfoot NJ. Intergenic transcription in the human beta-globin gene cluster. Mol Cell Biol 2001; 21: 6507-6514.
11. Routledge SJ, Proudfoot NJ. Definition of transcriptional promoters in the human beta globin locus control region. J Mol Biol 2002; 323: 601-611.
12. Long Q, Bengra C, Li C, Kutlar F, Tuan D. A long terminal repeat of the human endogenous retrovirus ERV-9 is located in the 5' boundary area of the human beta-globin locus control region. Genomics 1998; 54: 542-555.
13. Strazzullo M, Parisi T, Di Cristofano A, Rocchi M, La Mantia G. Characterization and genomic mapping of chimeric ERV9 endogenous retroviruses-host gene transcripts. Gene 1998; 206: 77-83.
14. Ling J, Pi W, Bollag R, Zeng S, Keskintepe M, Saliman H., et al. The solitary long terminal repeats of ERV-9 endogenous retrovirus are conserved during primate evolution and possess enhancer activities in embryonic and hematopoietic cells. J Virol 2002; 76: 2410-2423.
15. Zhao X, Liu X, Su L. Parthenolide induces apoptosis via TNFRSF10B and PMAIP1 pathways in human lung cancer cells. J Exp Clin Cancer Res 2014; 33: 3.
16. Jalving M, Heijink DM, Koornstra JJ, Boersma-van Ek W, Zwart N, Wesseling J., et al. Regulation of TRAIL receptor expression by beta-catenin in colorectal tumours. Carcinogenesis 2014; 35: 1092-1099.
17. Meijer A, Kruyt FA, van der Zee AG, Hollema H, Le P, ten Hoor KA., et al. Nutlin-3 preferentially sensitises wild-Type p53-Expressing cancer cells to DR5-selective TRAIL over rhTRAIL. Br J Cancer 2013; 109: 2685-2695.
18. Gupta SC, Francis SK, Nair MS, Mo YY, Aggarwal BB. Azadirone, a limonoid tetranortriterpene, induces death receptors and sensitizes human cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) through a p53 protein-independent mechanism: evidence for the role of the ROS-ERK-CHOP-Death receptor pathway. J Biol Chem 2013; 288: 32343-32356.
19. Lee DH, Lee CS, Kim DW, Ae JE, Lee TH. Digitoxin sensitizes glioma cells to TRAILmediated apoptosis by upregulation of death receptor 5 and downregulation of survivin. Anticancer Drugs 2014; 25: 44-52.
20. Ungefroren H, Voss M, Jansen M, Roeder C, Henne-Bruns D, Kremer B., et al. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res 1998; 58: 1741-1749.
21. Abaan OD, Levenson A, Khan O, Furth PA, Uren A, Toretsky JA. PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis. Oncogene 2005; 24: 2715-2722.
22. Steensma DP, Neiger JD, Porcher JC, Keats JJ, Bergsagel PL, Dennis TR., et al. Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes. Cancer Res 2009; 69: 7518-7523.
23. Ishida T, Ueda R. Immunopathogenesis of lymphoma: focus on CCR4. Cancer Sci 2011; 102: 44-50.
24. Candi E, Agostini M, Melino G, Bernassola F. How the TP53 family proteins TP63 and TP73 contribute to tumorigenesis: regulators and effectors. Hum Mutat 2014; 35: 702-714.
25. Reddy RM, Yeow WS, Chua A, Nguyen DM, Baras A, Ziauddin MF., et al. Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondriamediated caspase activation cascade. Apoptosis 2007; 12: 55-71.
26. Zhang J, Zhong Q. Histone deacetylase inhibitors and cell death. Cell Mol Life Sci 2014; 71: 3885-3901.
27. Lopez-Sanchez P, Costas JC, Naveira HF. Paleogenomic record of the extinction of human endogenous retrovirus ERV9. J Virol 2005; 79: 6997-7004.
28. Spierings DC, de Vries EG, Vellenga E, van den Heuvel FA, Koornstra JJ, Wesseling J., et al. Tissue distribution of the death ligand TRAIL and its receptors. J Histochem 52: 821-831.
29. Shetty S, Graham BA, Brown JG, Hu X, Vegh-Yarema N, Harding G., et al. Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol Cell Biol 2005; 25: 5404-5416.
30. Fandy TE, Shankar S, Ross DD, Sausville E, Srivastava RK. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 2005; 7: 646-657.
31. Cao H, Cheng Y, You L, Qian J, Qian W. Homoharringtonine and SAHA synergistically enhance apoptosis in human acute myeloid leukemia cells through upregulation of TRAIL and death receptors. Mol Med Rep 2013; 7: 1838-1844.
32. Singh TR, Shankar S, Srivastava RK. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 2005; 24: 4609-4623.
33. Kohany O, Gentles AJ, Hankus L, Jurka J. Annotation, submission and screening of repetitive elements in Repbase: RepbaseSubmitter and Censor. BMC Bioinformatics 2006; 7: 474.
34. Wu GS, Burns TF, McDonald ER 3rd, Jiang W, Meng R, Krantz ID., et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997; 17: 141-143.
35. Takimoto R, El-Deiry WS. Wild-Type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 2000; 19: 1735-1743.
36. Koster R, van Vugt MA, Timmer-Bosscha H, Gietema JA, de Jong S. Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer. Expert Rev Mol Med 2013; 15: e12.
37. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7: 573-584.
38. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33: 9-23.
39. Sprauten M, Darrah TH, Peterson DR, Campbell ME, Hannigan RE, Cvancarova M., et al. Impact of long-Term serum platinum concentrations on neuro-And ototoxicity in Cisplatintreated survivors of testicular cancer. Clin Oncol 2012; 30: 300-307.
40. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70: 440-446.
41. Singh SB, Davis AS, Taylor GA, Deretic V. Human IRGM induces autophagy to eliminate intracellular mycobacteria. Science 2006; 313: 1438-1441.
42. Singh SB, Ornatowski W, Vergne I, Naylor J, Delgado M, Roberts E., et al. Human IRGM regulates autophagy and cell-Autonomous immunity functions through mitochondria. Nat Cell Biol 2010; 12: 1154-1165.
43. McCarroll SA, Huett A, Kuballa P, Chilewski SD, Landry A, Goyette P., et al. Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn's disease. Nat Genet 2008; 40: 1107-1112.
44. Brest P, Lapaquette P, Souidi M, Lebrigand K, Cesaro A, Vouret-Craviari V., et al. A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-Dependent xenophagy in Crohn's disease. Nat Genet 2011; 43: 242-245.
45. Stachel I, Geismann C, Aden K, Deisinger F, Rosenstiel P, Schreiber S., et al. Modulation of nuclear factor E2-related factor-2 (Nrf2) activation by the stress response gene immediate early response-3 (IER3) in colonic epithelial cells: a novel mechanism of cellular adaption to inflammatory stress. J Biol Chem 2014; 289: 1917-1929.
46. Hasler R, Kerick M, Mah N, Hultschig C, Richter G, Bretz F., et al. Alterations of pre-mRNA splicing in human inflammatory bowel disease. Eur J Cell Biol 2011; 90: 603-611.
47. Arlt A, Schafer H. Role of the immediate early response 3 (IER3) gene in cellular stress response, inflammation and tumorigenesis. Eur J Cell Biol 2011; 90: 545-552.
48. Pawlikowska P, Leray I, de Laval B, Guihard S, Kumar R, Rosselli F., et al. ATM-Dependent expression of IEX-1 controls nuclear accumulation of Mcl-1 and the DNA damage response. Cell Death Differ 2010; 17: 1739-1750.
49. Yang YM, Feng AL, Zhou CJ, Liang XH, Mao HT, Deng BP., et al. Aberrant expression of chemokine receptor CCR4 in human gastric cancer contributes to tumor-induced immunosuppression. Cancer Sci 2011; 102: 1264-1271.
50. Lian F, Xing X, Yuan G, Schafer C, Rauser S, Walch A., et al. Farnesoid X receptor protects human and murine gastric epithelial cells against inflammation-induced damage. Biochem J 2011; 438: 315-323.
51. Boekelheide K, Lee J, Shipp EB, Richburg JH, Li G. Expression of Fas system-related genes in the testis during development and after toxicant exposure. Toxicol Lett 1998; 102-103: 503-508.
52. Castilla C, Chinchon D, Medina R, Torrubia FJ, Japon MA, Saez C. PTPL1 and PKCdelta contribute to proapoptotic signalling in prostate cancer cells. Cell Death Dis 2013; 4: e576.
53. Costas J, Naveira H. Evolutionary history of the human endogenous retrovirus family ERV9. Mol Biol Evol 2000; 17: 320-330.
54. Wang J, Xie G, Singh M, Ghanbarian AT, Rasko T, Szvetnik A., et al. Primate-specific endogenous retrovirus-Driven transcription defines naive-like stem cells. Nature 2014; 516: 405-409.
55. Pi W, Yang Z, Wang J, Ruan L, Yu X, Ling J., et al. The LTR enhancer of ERV-9 human endogenous retrovirus is active in oocytes and progenitor cells in transgenic zebrafish and humans. Proc Natl Acad Sci USA 2004; 101: 805-810.
56. Yu X, Zhu X, Pi W, Ling J, Ko L, Takeda Y., et al. The long terminal repeat (LTR) of ERV-9 human endogenous retrovirus binds to NF-Y in the assembly of an active LTR enhancer complex NF-Y/MZF1/GATA-2. J Biol Chem 2005; 280: 35184-35194.
57. Xu L, Elkahloun AG, Candotti F, Grajkowski A, Beaucage SL, Petricoin EF., et al. A novel function of RNAs arising from the long terminal repeat of human endogenous retrovirus 9 in cell cycle arrest. J Virol 2013; 87: 25-36.
58. Liu J, Edagawa M, Goshima H, Inoue M, Yagita H, Liu Z., et al. Role of ATF3 in synergistic cancer cell killing by a combination of HDAC inhibitors and agonistic anti-DR5 antibody through ER stress in human colon cancer cells. Biochem Biophys Res Commun 2014; 445: 320-326.
59. Coureuil M, Ugolin N, Tavernier M, Chevillard S, Barroca V, Fouchet P., et al. Puma and Trail/ Dr5 pathways control radiation-induced apoptosis in distinct populations of testicular progenitors. PLoS One 2010; 5: e12134.
60. McKee CM, Ye Y, Richburg JH. Testicular germ cell sensitivity to TRAIL-induced apoptosis is dependent upon p53 expression and is synergistically enhanced by DR5 agonistic antibody treatment. Apoptosis 2006; 11: 2237-2250.
61. Hannah NH, Einhorn LH. Testicular cancer-Discoveries and updates. N Engl J Med 2014; 371: 2005-2016.
62. Oosterhuis JW, Looijenga LH. Testicular germ-cell tumours in a broader perspective. Nat Rev Cancer 2005; 5: 210-222.
63. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007; 12: 1247-1252.
64. Goodman M. The genomic record of Humankind's evolutionary roots. Am J Hum Genet 1999; 64: 31-39.